Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
Nom du journal : BMC Cancer
Année : 2018
Volume : 18
Page de départ : 963